The PRISM Intervention for Adolescents and Young Adults Receiving Hematopoietic Cell Transplantation

The Promoting Resilience in Stress Management (PRISM) Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults Receiving Hematopoietic Cell Transplantation

Multisite Randomized Controlled Trial (RCT) testing the efficacy of the Promoting Resilience in Stress Management (PRISM) intervention among Adolescents and Young Adults receiving hematopoietic cell transplantation for hematology malignancy.

Study Overview

• Status: Completed
• Conditions: Depression; Quality of Life; Cancer; Anxiety; Adherence, Medication; Coping Skills; Bone Marrow Neoplasms; Adolescent Behavior
• Intervention / Treatment: Behavioral: PRISM (Promoting Resilience in Stress Management)

Detailed Description

The experience of hematopoietic cell transplantation (HCT) for malignancy or cancer predisposition among Adolescents and Young Adults (AYAs) is particularly difficult because age-related developmental challenges of identity, relationships, and vocation may add to the burden of cancer. Compared to other age-groups, AYAs have poorer psychosocial outcomes including increased anxiety and depression and poorer adherence to oral immunosuppressive medications. These outcomes may, in turn, predispose AYAs to disease-related morbidity and mortality such as graft-versus-host disease (GVHD) and/or cancer-relapse. A potential barrier to improving these experiences may be that AYAs have few opportunities to develop the personal resources needed to handle adversity. We have previously developed the "Promoting Resilience in Stress Management" (PRISM) intervention for AYAs with serious illness. This manualized, brief intervention is delivered in 4, 30-60 minute, one-on-one sessions, followed by a Parent/ Caregiver/ Spouse/ significant other inclusive meeting. It targets skills in stress-management and mindfulness, goal-setting, positive reframing, and meaning-making. All of these skills are associated with improved patient well-being in other populations, and preliminary findings from a recently closed phase II randomized controlled trial among AYAs with newly diagnosed cancer suggest PRISM is associated with improved health-related quality of life. This study will build on our prior experience and fill a critical knowledge gap regarding PRISM's impact among AYAs receiving HCT. Thus, we will conduct a multi-site randomized controlled trial with the primary trial outcome of patient-reported symptoms of anxiety and depression. Secondary and exploratory outcomes will include the cost-effectiveness of the intervention in this population, the impact of the intervention on parent well-being, and patient adherence to oral graft-versus-host-disease medications. We hypothesize that AYAs who receive PRISM will report fewer mixed affective symptoms, while their parents report improved quality of life and psychological distress. We also anticipate the intervention will positively impact adherence and be cost-effective. In sum, this study offers an opportunity to expand the body of knowledge regarding methodologically rigorous and evidence-based psychosocial interventions and standards of care for AYAs with hematologic malignancies. Ultimately, this research has the potential to reduce the burden of cancer in these vulnerable populations.

• Study Type: Interventional
• Enrollment (Actual): 143
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Birmingham, Alabama, United States, 35233
      • University of Alabama, Birmingham
  • California
    • Los Angeles, California, United States, 90027
      • Children's Hospital of Los Angeles
  • Massachusetts
    • Boston, Massachusetts, United States, 02215
      • Dana-Farber/Harvard Cancer Center
  • Tennessee
    • Memphis, Tennessee, United States, 38105
      • St. Jude Children's Research Hospital
  • Washington
    • Seattle, Washington, United States, 98145
      • Seattle Children's Hospital Cancer and Blood Disorders Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 12 years to 24 years (Child, Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria for adolescent/young adult (AYA) patient:

• Patient aged 12-24 years
• Receiving hematopoietic cell transplantation (HCT) for malignancy or cancer predisposition syndrome
• Within 4 weeks of HCT "day zero"
• Able to speak English
• Able to read English or Spanish
• Cognitively able to participate in interviews

Exclusion Criteria for AYA patient:

• Patient refusal
• Cognitively or physically unable to participate in interviews
• Unable to speak English
• Unable to read English or Spanish

For enrolled caregivers of AYA patient (no age limit):

Inclusion criteria:

• AYA Child of caregiver agreed to participate
• One caregiver per patient-caregiver dyad
• Parent/guardian cognitively and physically able to participate
• Parent/guardian is able to speak/read English or Spanish

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Health Services Research
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PRISM (Promoting Resilience in Stress Management); Resilience Skills Training	Behavioral: PRISM (Promoting Resilience in Stress Management); Manualized Skills-Training Program targeting resilience resources: stress-management, goal-setting, cognitive reframing, and meaning-making
No Intervention: Usual Care; Usual psychosocial care (control arm, no intervention)
No Intervention: Caregivers; Caregivers of participants, no intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Hospital Anxiety & Depression Scale (HADS) Score - Depression Sub-score	The Hospital Anxiety and Depression Scale -Depression sub scale assesses mixed affective symptoms in patients with serious illness. The scale consists of 7 questions for depression. Each is scored from 0-3, for a total range of 0-21 points. "Caseness" of depression is defined as ≥8 points, with sensitivity/specificity of 0.8/0.8 for depression. The depression sub-scale will be measured as a continuous variable. Higher scores indicate more symptoms.	6-months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Hope Scale Scores	The Snyder "Hope" Scale measures "the overall perception that one's goals can be met." The instrument scored on an 8-point Likert scale (score range 0-64). Higher scores imply greater levels of hopeful thought patterns.	6-months
PedsQL Generic Core and Cancer-Related Quality of Life Score	The PedsQL 4.0 Generic and 3.0 Cancer Module include 50 items evaluating health-related quality of life of adolescents and young adults (AYAs) with cancer. Items are rated on a 5-point Likert scale and total scores transformed to a 0-100 scale with higher scores representing better HRQOL. Internal consistency ranges from 0.75 to 0.92.	6-months
Connor-Davidson Resilience Scale	The Connor-Davidson Resilience Scale (CD-RISC) measures inherent resiliency. The 10-item instrument has high internal consistency. Each item consists of a 5-point Likert scale (scored from zero to four). ranging from 0-40 with higher scores reflecting greater perceived resilience.	6-months
Hospital Anxiety & Depression Scale Score - Anxiety Sub-score	The Hospital Anxiety and Depression Scale - Anxiety sub scale assesses mixed affective symptoms in patients with serious illness. It consists of 7 questions on a 3 point Likert scale for a total range of 0-21. Higher scores indicate higher anxiety.	6-months
Generalized Anxiety Disorder Screener (GAD7)	7-item survey used to assess anxiety symptoms. Scored from 0-21 with higher scores indicated higher anxiety.	6-months
Patient Health Questionnaire-8	8-item survey assessing depression severity. Each item scored on a 4-point Likert scale with a range of 0-27. Higher scores indicate higher depression.	6-months
Medical Outcomes Study Rand 36-item Health Survey	This is a measure of health-related quality of life. Scores range from 0-100 and higher scores indicate better health status	6-months

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Impact of PRISM on heart-rate variability	Exploratory aim: A subset of patients will participate in an optional companion study to evaluate the impact of PRISM on Heart Rate Variability as a biomarker of stress	6-months

Collaborators and Investigators

• Sponsor: Seattle Children's Hospital
• Collaborators: National Cancer Institute (NCI); University of Alabama at Birmingham; St. Jude Children's Research Hospital; Children's Hospital Los Angeles
• Investigators: Principal Investigator: Abby R Rosenberg, MD, MS, MA, Dana-Farber Cancer Institute

Publications and helpful links

General Publications

• Fladeboe KM, Scott S, Comiskey L, Zhou C, Yi-Frazier JP, Rosenberg AR. The Promoting Resilience in Stress Management (PRISM) intervention for adolescents and young adults receiving hematopoietic cell transplantation: a randomized controlled trial protocol. BMC Palliat Care. 2022 May 19;21(1):82. doi: 10.1186/s12904-022-00966-9.

Study record dates

Study Major Dates

• Study Start (Actual): April 1, 2019
• Primary Completion (Actual): March 31, 2023
• Study Completion (Actual): March 31, 2024

Study Registration Dates

• First Submitted: August 15, 2018
• First Submitted That Met QC Criteria: August 17, 2018
• First Posted (Actual): August 21, 2018

Study Record Updates

• Last Update Posted (Actual): October 26, 2024
• Last Update Submitted That Met QC Criteria: October 23, 2024
• Last Verified: October 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Hematologic Diseases; Bone Marrow Diseases; Hematologic Neoplasms; Bone Marrow Neoplasms
• Other Study ID Numbers: STUDY00001077 (SC-N126); R01CA225629 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: All IPD will be protected and maintained by the study team

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No